Compare The Coca-Cola Co K (KO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Repligen Corporation Common Stock — how do they compare? The Coca-Cola Co K trades at $92.84 (market cap $387.70B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: The Coca-Cola Co K is far larger — about 34.8× Repligen Corporation Common Stock's market cap, and The Coca-Cola Co K pays a 2.35% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Repligen Corporation Common Stock for 0 Days on average.
| KO | RGEN | |
|---|---|---|
Market Cap | $387.70B | $11.14B |
Volume | 15,313,783 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $194.57 |
52-Week Low | $67.08 | $102.87 |
Typical Hold Time | 154 Days | 0 Days |
Enterprise Value | $414.87B | $11.02B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $90.11, up 0.36% with strong technical momentum as it approaches resistance near $91. The company demonstrates robust fundamentals with Q2 2026 EPS of $0.97 beating expectations, maintaining a 61.89% gross margin and 28.56% net margin. Recent institutional buying activity and the upcoming $0.53 dividend payment reflect positive sentiment. The stock trades at a P/E of 27.06, above sector averages, while analyst consensus targets $95.75 with 60% buy ratings.
Outlook remains favorable with projected 2026 revenue growth to $50.1B and net income of $14.3B. Key risks include high valuation multiples and regional demand divergence. The technical setup suggests near-term consolidation with support at $88, while fundamental strength supports long-term dividend growth potential.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
